Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?
Guy's & St. Thomas' Hospitals, St Thomas' Hospital Campus, London, UK.
A S
AS
Wierzbicki
R
R
Louis
D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D050197:Atherosclerosis / Q000517:prevention & control; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008074:Lipoproteins / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D051379:Mice; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008074:Lipoproteins